Breaking News

Samsung BioLogics Wins First Contract for Plant 3 Facility

Facility has 180,000 liters total capacity and is expected to be cGMP operational by 4Q18

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Samsung BioLogics, headquartered in Incheon, South Korea, has entered into the first manufacturing contract for its Plant 3 facility. According to the company, the contract is valued at approximately $148 million, if the product is successful in clinical development and moves to commercial launch.   The Plant 3 facility was completed last November and has 180,000 liters total capacity and is expected to be cGMP operational by 4Q18. TH Kim, chief executive officer of Samsung BioLogics, said,...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters